Can AI Rewrite the Rules of Clinical Trials?

DarshanTalks Podcast

In this episode, we're diving into the intersection of technology and healthcare, specifically the role of Artificial Intelligence (AI) in clinical trials. As a Food and Drug lawyer, Darshan has seen firsthand how AI is revolutionizing drug development and testing. The FDA is closely monitoring this shift, recognizing the potential of AI to enhance patient outcomes, improve trial efficiency, and reduce costs.

However, it’s not all smooth sailing. AI can help identify the right patients for specific treatments, but it’s crucial to address potential biases in AI algorithms, which could affect diversity in clinical trials. AI can also streamline trial processes, but the “black box” nature of how decisions are made raises concerns about transparency and fairness. Cost reduction is often touted, yet we’re still waiting to see if AI will truly lower expenses in the long run.

Data privacy and security are also big considerations. With AI relying on massive data sets, how can we ensure patient privacy is protected? And who truly owns the data? Algorithmic bias is another serious concern—especially when it comes to underrepresented patient populations.

The FDA is working on issuing guidance for AI in clinical trials, but we’re still in the early stages. They are encouraging collaboration between industry, academia, and other stakeholders to develop best practices. Plus, the FDA is investing in research to better understand both the benefits and risks of AI in healthcare.

In the end, AI’s potential is enormous, but we need to be careful about how it’s implemented. What do you think are the biggest challenges when using AI in clinical trials? Drop your thoughts in the comments!

And if you’re a drug or medical device company looking to leverage AI, reach out to us at Kulkarni Law Firm for legal guidance through the complex regulatory landscape. Visit our website for more info.

Support the show